Search Results 651-660 of 17207 for ibd

  1. Publications - Dora M. Lam-Himlin, M.D. - Mayo Clinic

    Classification and diagnosis of colorectal dysplasia in inflammatory bowel disease. Diagn Histopathol. 2015; 21(7):283-9. Arnold CA, Bhaijee F, Lam-Himlin D.

  2. Meet Our Fellows - Pediatric Gastroenterology Fellowship (Minnesota) - Mayo Clinic College of Medicine & Science

    Pediatric inflammatory bowel disease is a passion of mine that initially sparked my interest in pediatric gastroenterology. Additionally, during my ...

  3. Vedolizumab Subcutaneous Long-Term Open-Label Extension Study - Mayo Clinic

    Surgical intervention for IBD during or after participation in Study MLN0002SC-3027 or MLN0002SC-3031, or at any time during this study. Chronic or severe ...

  4. Academics - Find a Program at Mayo Clinic College of Medicine & Science

    Gastroenterology, Inflammatory Bowel Disease Fellowship (Minnesota). Type: Fellowship; Duration: 1 year; School: Graduate Medical ...

  5. Health & Wellness - Page 94 of 810 - Mayo Clinic News Network

    Inflammatory bowel disease (IBD) is a chronic inflammation of the digestive tract. It includes conditions such as ulcerative colitis and Crohn's disease ...

  6. Publications - Search Publications by Mayo Clinic Authors - Mayo Clinic Research

    Association of Vitamin D Level With Clinical Status in Inflammatory Bowel Disease: A 5-Year Longitudinal Study. Kabbani TA ...

  7. Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease - Mayo Clinic

    ... inflammatory bowel disease. In combination with medical therapies, surgical management of perianal fistulas is important for both infection control and ...

  8. Infliximab-Qbtx (Intravenous Route) Description and Brand Names - Mayo Clinic

    Infliximab-qbtx injection is used to reduce the symptoms of moderate-to-severely active Crohn's disease and ulcerative colitis in adults and children who have ...

  9. Head-to-head comparison between vedolizumab and adalimumab for treatment of moderately to severely active ulcerative colitis - Mayo Clinic

    The Food and Drug Administration approved the use of anti-tumor necrosis factor and anti-integrin agents for the treatment of ulcerative colitis in 2005 ...

  10. Survey examines attitudes about ESG from providers around the world - Mayo Clinic

    Examining the use of endoscopic bariatric therapy in patients with IBD. MAC-20527800. Medical Professionals; Survey examines attitudes about ESG from providers ...